课题基金 / 基金详情

The ARF Tumor Suppressor

The ARF Tumor Suppressor
ARF肿瘤抑制剂
批准号:
8205015
负责人:
Maureen E. Murphy
金额:
$34.08万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-01-01 至 2014-12-31

项目摘要

项目成果

Maureen E. Murphy的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The ARF tumor suppressor protein is encoded by the Ink4a/ARF gene, which is the second most frequently mutated genetic locus in human cancer. To date the majority of research on ARF has focused on its tumor suppressor functions. This proposal focuses instead on a novel survival function for ARF that we have recently uncovered, and that exists for a subset of tumors with mutant/null p53. We show that ARF plays an integral role in starvation-induced autophagy. Autophagy is a self-catabolic process that promotes the survival of cells exposed to nutrient deprivation. Because tumor cells exist under uniquely metabolically-stressed conditions, many rely heavily on this pathway in order to subsist. Consistent with this fact, autophagy inhibitors have shown promise as anti-cancer agents. We show that ARF protein is markedly up-regulated in response to nutrient deprivation. We show that silencing ARF impedes autophagy and decreases the survival of nutrient-deprived cells. Finally, we show that silencing ARF in lymphomas impairs autophagy and survival, and actually impedes the development of these tumors. The central hypothesis of this proposal is that ARF-mediated autophagy is utilized by a subset of tumors with mutant p53 to allow them to survive episodes of metabolic stress. We contend that the requirement for the survival function of autophagy is an 'Achilles heel' for tumors. We need to better understand this pathway in order to exploit it for cancer therapy. In proposed research we will elucidate the mechanism(s) whereby ARF induces autophagy. We will determine how nutrient deprivation leads to increased ARF protein levels. We have found that ARF expression is beneficial for some tumors (lymphoma) but not others (sarcoma); we will define the subset of tumors that are benefited by ARF-mediated autophagy. We will determine whether critical mediators of autophagy, such as ARF and Beclin1, dictate tumor response to small molecules that modulate this process, such as chloroquine (inhibits autophagy), and trehalose (induces autophagy). Finally we will elucidate the mechanism of transcriptional repression of the ARF locus by p53, as this leads to ARF up-regulation in p53-mutant tumors. The combined data will serve as a necessary foundation for exploiting the pathway of autophagy for cancer therapy. PUBLIC HEALTH RELEVANCE: The ARF gene is encoded by the Ink4a/ARF locus, which is the second most commonly mutated genetic locus in human cancer; up to 50% of human tumors contain mutations in Ink4a/ARF. This fact argues that research aimed at understanding the basic function of ARF in human cancer is warranted. We show that ARF controls a key survival pathway for tumor cells. We believe that the requirement for ARF and autophagy may be an Achilles Heel for tumor cells. This research is aimed at understanding this pathway, and at finding ways to manipulate this pathway to combat cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Functional Analysis of p53 Polymorphic Variants - Diversity Supplement
  • 批准号:
    10818904
  • 项目类别:
  • 资助金额:
    $4.37万
  • 财政年份:
    2023
  • 负责人:
    Maureen E. Murphy
  • 依托单位:
The genetics of tumor suppression by p53
  • 批准号:
    10636305
  • 项目类别:
  • 资助金额:
    $42.22万
  • 财政年份:
    2023
  • 负责人:
    Maureen E. Murphy
  • 依托单位:
Purchase of a SARRP 200 Platform for Irradiation
  • 批准号:
    10430904
  • 项目类别:
  • 资助金额:
    $60.0万
  • 财政年份:
    2022
  • 负责人:
    Maureen E. Murphy
  • 依托单位:
The impact of coding region variants on mutant p53 biology
  • 批准号:
    10304135
  • 项目类别:
  • 资助金额:
    $43.6万
  • 财政年份:
    2019
  • 负责人:
    Maureen E. Murphy
  • 依托单位:
国内基金
海外基金
神经元缺血性"程序性坏死"调控机制及3-methyladenine保护机制研究
  • 批准号:
    81100877
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    22.0万元
  • 批准年份:
    2011
  • 负责人:
    汪敬业
  • 依托单位: